Millions of men in the U.S. are now being actively managed for prostate disorders such as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis, with approximately 3.3 million new prostate disorder cases occurring annually.

In 2006, prostate disorder diagnostic and therapeutic modalities were employed in approximately 35.5 million diagnostic procedures and 5.0 million therapeutic procedures in the U.S., which generated approximately $4.5 billion in corresponding product revenues. The number of prostate disorder-specific diagnostic and therapeutic procedures performed in the U.S. is projected to expand to 41.3 million diagnostic procedures and 6.3 million therapeutic procedures, while combined prostate disorder-specific diagnostic and treatment product revenues are forecast to grow at a compound annual rate of 5.7%, with revenues increasing to an estimated $5.9 billion in the year 2011.

This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. market for diagnostic and therapeutic prostate disorder management products.

Covered topics in this report include 5-alpha-reductase inhibitors; alpha blockers; anti-infectives; anti-inflammatory and analgesic agents; BPH, prostate cancer, and prostatitis etiology and epidemiology; combination drug therapies; cryotherapy; diagnostic imaging; external beam radiation therapy; high-intensity focused ultrasound therapy; hormonal therapy; microwave-, laser-, radiofrequency-, and water-based treatment systems; minimally invasive and surgical treatment procedures; permanent implantation brachytherapy systems; prostate biopsy systems; prostate-specific antigen testing products; prostatic stenting; radical prostatectomy; robotic-assisted surgery; systematic chemotherapy; transrectal ultrasonography systems; transurethral incision of the prostate; transurethral needle ablation; transurethral resection of the prostate; transurethral vaporization of the prostate; and urodynamic assessment systems.

Ordering Information

Print versions of Reports are available upon request for an additional fee.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i.       Prostate Disorders, Etiology and Epidemiology

ii.       Diagnostic Procedures and Products for the Management of Prostate Diseases/Disorders

iii.      Therapeutic Procedures and Products for the Management of Benign Prostatic Hyperplasia

iv.      Therapeutic Procedures and Products for the Management of Prostate Cancer

v.      Therapeutic Procedures and Products for the Management of Prostatitis

vi.      Combined Market Forecast

vii.     Methodology

Exhibit ES-1:    Major Prostate Diseases/Disorders, Incidence and Prevalence, 2006 and 2011

Exhibit ES-2:    Prostate Diseases/Disorders, Diagnostic Products, Market Forecast, 2005-2011

Exhibit ES-3:    Benign Prostatic Hyperplasia Therapy Products, Market Forecast, 2005-2011

Exhibit ES-4:    Prostate Cancer-Specific Treatment Products, Market Forecast, 2005-2011

Exhibit ES-5:    Prostatitis Treatment Products, Market Forecast, 2005-2011

Exhibit ES-6:    Total Diagnostic and Therapeutic Prostate Disease/Disorder Management Products, Market Forecast, 2005-2011

1. PROSTATE DISORDERS, ETIOLOGY, AND EPIDEMIOLOGY

1.1 Benign Prostatic Hyperplasia

1.1.1 Clinical Presentation

1.1.2 Etiology

1.1.3 Epidemiology

1.1.4 Diagnostic Procedures

1.1.5 Therapeutic Management

1.2 Prostate Cancer

1.2.1 Clinical Presentation

1.2.2 Etiology

1.2.3 Epidemiology

1.2.4 Diagnostic Procedures

1.2.5 Therapeutic Management

1.3 Prostatitis

1.3.1 Clinical Presentation

1.3.2 Etiology

1.3.3 Epidemiology

1.3.4 Diagnostic Procedures

1.3.5 Therapeutic Management

Exhibit 1-1:      2006, Benign Prostatic Hyperplasia, Facts and Figures

Exhibit 1-2:      Selected Tools and Techniques for the Diagnosis and Management of Benign Prostatic Hyperplasia

Exhibit 1-3:      2006, Prostate Cancer, Facts And Figures

Exhibit 1-4:      Selected Tools and Techniques for the Diagnosis and Management of Prostate Cancer

Exhibit 1-5:      2005, Prostatitis, Facts and Figures

Exhibit 1-6:      Selected Tools and Techniques for the Diagnosis and Management of Prostatitis

2. DIAGNOSTIC PROCEDURES AND PRODUCTS FOR THE MANAGEMENT OF PROSTATE DISEASES/DISORDERS

2.1 Diagnostic Tools and Techniques

2.1.1 Patient History

2.1.2 Digital Rectal Examination

2.1.3 Clinical Laboratory Studies

2.1.3.1 Urine and Blood Testing

2.1.3.2 Prostate-Specific Antigen Testing

2.1.3.2.1 Prostate-Specific Antigen Values

2.1.3.2.2 Free Prostate-Specific Antigen Assays

2.1.3.2.3 Complexed Prostate-Specific Antigen Assays

2.1.3.2.4 Prostate-Specific Antigen Reverse Transcription-Polymerase Chain Reaction Assays

2.1.3.3 Emerging Prostate Cancer Biomarkers

2.1.4 Urodynamic Studies

2.1.5 Diagnostic Imaging

2.1.5.1 Multipurpose Imaging Modalities

2.1.5.2 Transrectal Ultrasound

2.1.6 Tissue Biopsy

2.2 Clinical Practice Guidelines and Diagnostic Protocols

2.2.1 Benign Prostatic Hyperplasia

2.2.2 Prostate Cancer

2.2.3 Prostatitis

2.3 Application-Specific Diagnostic Products, Market Analysis

2.3.1 Prostate-Specific Antigen Assays

2.3.1.1 Products

2.3.1.2 Market Forecast

2.3.1.3 Competitive Analysis

2.3.2 Prostate Biopsy Systems

2.3.2.1 Products

2.3.2.2 Market Forecast

2.3.2.3 Competitive Analysis

2.3.3 Transrectal Ultrasonography Systems

2.3.3.1 Products

2.3.3.2 Market Forecast

2.3.3.3 Competitive Analysis

2.3.4 Urodynamic Assessment Systems

2.3.4.1 Products

2.3.4.2 Market Forecast

2.3.4.3 Competitive Analysis

Exhibit 2-1:      Normal Prostate-Specific Antigen Levels, by Age Group

Exhibit 2-2:      Prostate Cancer Probability Based on Prostate-Specific Antigen Results

Exhibit 2-3:      Urodynamic Assessment Tools and Techniques

Exhibit 2-4:      Recommended Pathways for the Diagnosis of Suspected Benign Prostatic Hyperplasia

Exhibit 2-5:      Tumor-Node-Metastasis Staging System of the American Joint Committee on Cancer

Exhibit 2-6:      Recommended Pathways for the Diagnosis of Suspected Prostate Cancer

Exhibit 2-7:      Prostate Disease/Disorders, Application-Specific Testing, Procedure Volumes Forecast, 2005-2011

Exhibit 2-8:      Prostate Diseases/Disorders, Diagnostic Products, Market Forecast, 2005-2011

Exhibit 2-9:      2007, Selected Prostate-Specific Antigen Testing Products

Exhibit 2-10:    Prostate-Specific Antigen Testing, Procedure Volumes Forecast, 2005-2011

Exhibit 2-11:    Prostate-Specific Antigen Testing Products, Market Forecast, 2005-2011

Exhibit 2-12:    2006, Prostate-Specific Antigen Testing Products Market, Share by Supplier

Exhibit 2-13:    2007, Selected Prostate Biopsy Products

Exhibit 2-14:    Prostate Biopsy, Procedure Volumes Forecast, 2005-2011

Exhibit 2-15:    Prostate Biopsy Devices, Market Forecast, 2005-2011

Exhibit 2-16:    2006, Prostate Biopsy Devices Market, Share by Supplier

Exhibit 2-17:    2007, Selected Transrectal Ultrasound-Capable Imaging Systems

Exhibit 2-18:    Transrectal Ultrasonography, Procedure Volumes Forecast, 2005-2011

Exhibit 2-19:    Transrectal Ultrasound-Capable Imaging Systems, Market Forecast, 2005-2011

Exhibit 2-20:    2006, Transrectal Ultrasound-Capable Imaging Systems Market, Share by Supplier

Exhibit 2-21:    2007, Selected Urodynamic Assessment Systems

Exhibit 2-22:    Urodynamic Assessment, Procedure Volumes Forecast, 2005-2011

Exhibit 2-23:    Urodynamic Assessment Systems, Market Forecast, 2005-2011

Exhibit 2-24:    2006, Urodynamic Assessment Systems Market, Share by Supplier

3. THERAPEUTIC PROCEDURES AND PRODUCTS FOR THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA

3.1 Approaches to the Therapeutic Management of Benign Prostatic Hyperplasia

3.1.1 Watchful Waiting

3.1.2 Drug Therapy

3.1.2.1 Alpha Blockers

3.1.2.2 5-Alpha Reductase Inhibitors

3.1.2.3 Combination Drug Therapy

3.1.2.4 Patient Volumes Forecast

3.1.3 Surgical Treatment

3.1.3.1 Transurethral Resection of the Prostate

3.1.3.2 Transurethral Incision of the Prostate

3.1.3.3 Transurethral Vaporization of the Prostate

3.1.3.4 Patient Volumes Forecast

3.1.4 Minimally Invasive Treatment

3.1.4.1 Transurethral Microwave Thermotherapy

3.1.4.2 Transurethral Needle Ablation

3.1.4.3 Laser-Based Therapy

3.1.4.3.1 Video Laser-Assisted Prostatectomy

3.1.4.3.2 Interstitial Laser Coagulation

3.1.4.3.3 Holmium Laser Enucleation of the Prostate

3.1.4.3.4 Photoselective Vaporization of the Prostate

3.1.4.4 Water-Induced Thermal Therapy

3.1.4.5 Procedure Volumes Forecast

3.1.5 Prostatic Stenting

3.1.5.1 Procedure Volumes Forecast

3.2 Drug- and Device-Based Benign Prostatic Hyperplasia Treatment Products, Market Analysis

3.2.1 Pharmaceuticals

3.2.1.1 Market Forecast

3.2.1.2 Competitive Analysis

3.2.2 Electrosurgical Devices

3.2.2.1 Products

3.2.2.2 Market Forecast

3.2.2.3 Competitive Analysis

3.2.3 Minimally Invasive Treatment Systems

3.2.3.1 Products

3.2.3.2 Market Forecast

3.2.3.3 Competitive Analysis

3.2.4 Prostatic Stenting Systems

3.2.4.1 Products

3.2.4.2 Market Forecast

Exhibit 3-1:      Benign Prostatic Hyperplasia, Drug Therapy, Patient Volumes Forecast, 2005-2011

Exhibit 3-2:      Benign Prostatic Hyperplasia-Related Surgery, Patient Volumes Forecast, 2005-2011

Exhibit 3-3:      Minimally Invasive Directed Energy-Based Benign Prostatic Hyperplasia Therapies, Procedure Volumes Forecast, 2005-2011

Exhibit 3-4:      Urethral/Prostatic Stenting, Procedure Volumes Forecast, 2005-2011

Exhibit 3-5:      Benign Prostatic Hyperplasia, Combined Patient Volumes Forecast, 2005-2011

Exhibit 3-6:      Benign Prostatic Hyperplasia Therapy Products, Combined Market Forecast, 2005-2011

Exhibit 3-7:      2007, Selected Benign Prostatic Hyperplasia Drugs

Exhibit 3-8:      Benign Prostatic Hyperplasia Drug Therapy Products, Patient Volumes and Market Forecast, 2005-2011

Exhibit 3-9:      2006, Benign Prostatic Hyperplasia Drugs Market, Share by Supplier

Exhibit 3-10:    2007, Selected Disposable Electrosurgical Devices

Exhibit 3-11:    Benign Prostatic Hyperplasia-Related Disposable Electrosurgical Devices,  Market Forecast, 2005-2011

Exhibit 3-12:    2006, Benign Prostatic Hyperplasia-Related Disposable Electrosurgical Devices Market, Share by Supplier

Exhibit 3-13:    2007, Selected Minimally Invasive Directed Energy-Based Benign Prostatic Hyperplasia Therapy Systems

Exhibit 3-14:    Minimally Invasive Directed Energy-Based Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2005-2011

Exhibit 3-15:    2006, Minimally Invasive Directed Energy-Based Benign Prostatic Hyperplasia Therapy Systems Market, Share by Supplier

Exhibit 3-16:    Urethral/Prostatic Stents, Market Forecast, 2005-2011

4. THERAPEUTIC PROCEDURES AND PRODUCTS FOR THE MANAGEMENT OF PROSTATE CANCER

4.1 Approaches to the Therapeutic Management of Prostate Cancer

4.1.1 Established and Emerging Therapeutic Modalities

4.1.1.1 Expectant Management

4.1.1.1.1 Patient Volumes Forecast

4.1.1.2 Radical Prostatectomy

4.1.1.2.1 Open Radical Prostatectomy

4.1.1.2.2 Laparoscopic Radical Prostatectomy

4.1.1.2.3 Procedure Volumes Forecast

4.1.1.3 External Beam Radiation Therapy

4.1.1.3.1 Conformal Radiation Therapy

4.1.1.3.2 Intensity-Modulated Radiation Therapy

4.1.1.3.3 Patient Volumes Forecast

4.1.1.4 Brachytherapy

4.1.1.4.1 Permanent Implantation

4.1.1.4.2 Temporary Implantation

4.1.1.4.3 Radioisotope Sources

4.1.1.4.4 Reimbursement

4.1.1.4.5 Patient Volumes Forecast

4.1.1.5 Cryotherapy

4.1.1.5.1 Reimbursement

4.1.1.5.2 Patient Volumes Forecast

4.1.1.6 High-Intensity Focused Ultrasound

4.1.1.6.1 Clinical Experience

4.1.1.6.2 Regulatory Status

4.1.1.6.3 Patient Volumes Forecast

4.1.1.7 Hormone Therapy

4.1.1.7.1 Hormone Therapy Regimens

4.1.1.7.2 Patient Volumes Forecast

4.1.1.8 Systemic Chemotherapy

4.1.1.8.1 Systematic Chemotherapy Regimens

4.1.1.8.2 Patient Volumes Forecast

4.2 Drug- and Device-Based Prostate Cancer Treatment Products, Market Analysis

4.2.1 Permanent Implantation Brachytherapy Systems

4.2.1.1 Products

4.2.1.2 Market Forecast

4.2.1.3 Competitive Analysis

4.2.2 Cryotherapy Systems

4.2.2.1 Products

4.2.2.2 Market Forecast

4.2.2.3 Competitive Analysis

4.2.3 Hormone Therapy Agents

4.2.3.1 Products

4.2.3.2 Market Forecast

4.2.3.3 Competitive Analysis

4.2.4 Systemic Chemotherapy Agents

4.2.4.1 Products

4.2.4.2 Market Forecast

4.2.4.3 Competitive Analysis

4.2.5 High-Intensity Focused Ultrasound Systems

4.2.5.1 Products

4.2.5.2 Market Forecast

Exhibit 4-1:      Therapeutic Protocols for Prostate Cancer Management

Exhibit 4-2:      Prostate Cancer, Expectant Management, Patient Volumes Forecast, 2005-2011

Exhibit 4-3:      Radical Prostatectomy, Procedure Volumes Forecast, 2005-2011

Exhibit 4-4:      External Beam Radiation Therapy, Patient Volumes Forecast,2005-2011

Exhibit 4-5:      Permanent Implantation Brachytherapy, Patient Volumes Forecast, 2005-2011

Exhibit 4-6:      Cryotherapy, Patient Volumes Forecast, 2005-2011

Exhibit 4-7:      High Intensity Focused Ultrasound Therapy, Patient Volumes Forecast, 2005-2011

Exhibit 4-8:      Prostate Cancer Hormone Therapy, Patient Volumes Forecast, 2005-2011

Exhibit 4-9:      Prostate Cancer Systemic Chemotherapy, Patient Volumes Forecast, 2005-2011

Exhibit 4-10:    Prostate Cancer Therapy, Procedure Volumes Forecast, 2005-2011

Exhibit 4-11:    Prostate Cancer-Specific Treatment Products, Market Forecast, 2005-2011

Exhibit 4-12:    2007, Selected Permanent Radioisotope Seed Implants

Exhibit 4-13:    Permanent Implantation Brachytherapy Products, Market Forecast, 2005-2011

Exhibit 4-14:    2006, Permanent Implantation Brachytherapy Products Market, Share by Supplier

Exhibit 4-15:    2007, Selected Cryotherapy Systems

Exhibit 4-16:    Cryotherapy Products, Market Forecast, 2005-2011

Exhibit 4-17:    2006, Cryotherapy Products Market, Share by Supplier

Exhibit 4-18:    2007, Selected Prostate Cancer-Related Hormone Therapy Products

Exhibit 4-19:    Prostate Cancer-Related Hormone Therapy Products, Market Forecast, 2005-2011

Exhibit 4-20:    2006, Prostate Cancer-Related Hormone Therapy Products, Share by Supplier

Exhibit 4-21:    2007, Selected Prostate Cancer-Related Systemic Chemotherapy Products

Exhibit 4-22:    Prostate Cancer-Related Systemic Chemotherapy Products, Market Forecast, 2005-2011

Exhibit 4-23:    2006, Prostate Cancer-Related Systemic Chemotherapy Products Market, Share by Supplier

Exhibit 4-24:    2007, Selected High-Intensity Focused Ultrasound Systems

Exhibit 4-25:    High-Intensity Focused Ultrasound Systems, Market Forecast, 2005-2011

5. THERAPEUTIC PROCEDURES AND PRODUCTS FOR THE MANAGEMENT OF PROSTATITIS

5.1 Approaches to the Therapeutic Management of Prostatitis

5.1.1 Drug Therapy

5.1.1.1 Antibiotics

5.1.1.2 Anti-Inflammatory and Analgesic Agents

5.1.1.3 Narcotic Drugs

5.1.1.4 Alpha Blockers

5.1.2 Surgical Treatment

5.1.3 Minimally Invasive Treatment

5.1.3.1 Microwave-Based Thermal Therapy

5.1.3.1.1 Transrectal Approach

5.1.3.1.2 Transurethral Approach

5.1.3.2 Radiofrequency-Based Thermal Therapy

5.1.3.3 Water-Based Thermal Therapy

5.1.4 Drug- and Device-Based Prostatitis Treatment Products, Market Analysis

5.1.4.1 Products

5.1.4.2 Market Forecast

Exhibit 5-1:      Selected Clinical Trials, Minimally Invasive Thermal Therapy for Prostatitis/ Chronic Pelvic Pain Syndrome

Exhibit 5-2:      Advantages and Disadvantages of Minimally Invasive Thermal Therapy for Prostatitis/Chronic Pelvic Pain Syndrome

Exhibit 5-3:      Prostatitis Interventions, Patient Volumes Forecast, 2005-2011

Exhibit 5-4:      Prostatitis Treatment Products, Market Forecast, 2005-2011

6. COMPANY PROFILES

6.1       Abbott Laboratories

6.2       American Medical Systems Holdings, Inc.

6.3       AstraZeneca PLC

6.4       Bard Biopsy Systems/Bard Peripheral Vascular, Inc./C.R. Bard, Inc.

6.5       Bayer AG

6.6       Beckman Coulter, Inc.

6.7       B-K Medical/Analogic Corporation

6.8       Boehringer Ingelheim GmbH/C.H. Boehringer Sohn

6.9       Boston Scientific Corporation

6.10     Bristol-Myers Squibb Company

6.11     Endocare, Inc.

6.12     GE Healthcare/General Electric Company

6.13     GlaxoSmithKline PLC

6.14     Gyrus ACMI, Inc./Gyrus Group PLC

6.15     Laborie Medical Technologies, Inc.

6.16     Life-Tech, Inc.

6.17     Medtronic, Inc.

6.18     Merck & Company, Inc.

6.19     sanofi-aventis SA

6.20     Urologix, Inc.

 APPENDIX:  COMPANY LISTING